Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Commentary on: OpenUrl
For widely prescribed medications, such as statins, even the development of uncommon adverse events may have significant public health ramifications. Recent meta-analyses of randomised controlled trials (RCTs) have demonstrated an increased incidence of diabetes in patients taking statins. These have demonstrated a dose–effect relationship, but whether different statins have differential effects on the risk of diabetes is still unclear. In this study, Carter and colleagues further investigate the dose–effect relationship of statin-induced diabetes and whether different statins carry distinct risks of diabetes in a large, real-world population.
The authors examined healthcare records of more than 1.5 million adults aged 66 years or above in Ontario, Canada from August 1997 to March 2010. The analysis excluded patients with established diabetes and those prescribed a statin within 1 year prior to the start of the study. Linked administrative healthcare databases were used to provide information on …
Competing interests DLB is on the advisory board for Elsevier Practice Update Cardiology, Medscape Cardiology, and Regado Biosciences. He is also on the board of directors for the Boston VA Research Institute, the Society of Cardiovascular Patient Care and is chair of the American Heart Association Get With The Guidelines Steering Committee. He has received honoraria from the American College of Cardiology (Editor, Clinical Trials, Cardiosource), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), Population Health Research Institute (clinical trial steering committee), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), and WebMD (CME steering committees). Additionally, he is on Data Monitoring Committees for Duke Clinical Research Institute, Mayo Clinic and the Population Health Research Institute. He has received research grants from Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Sanofi, and The Medicines Company and also has done unfunded research with FlowCo, PLx Pharma, and Takeda. Lastly, he is on the Executive Committee of ODYSSEY (a cardiovascular outcome study of a PCSK9 inhibitor made by Sanofi).